首页 > 最新文献

Synthetic biology (Oxford, England)最新文献

英文 中文
Variability in genome-engineering source materials: consider your starting point. 基因组工程源材料的可变性:考虑你的出发点。
Q2 BIOCHEMICAL RESEARCH METHODS Pub Date : 2023-01-01 DOI: 10.1093/synbio/ysad003
Simona Patange, Sierra D Miller, Samantha D Maragh

The presence and impact of variability in cells as the source material for genome engineering are important to consider for the design, execution and interpretation of outcomes of a genome-engineering process. Variability may be present at the genotype and phenotype level, yet the impact of these sources of variability on a genome-engineering experiment may not be regularly considered by researchers. In this perspective, we use clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated protein (Cas) genome editing of mammalian cells to provide examples of how variation within or across cell samples may mislead a researcher in their expectations about the cells they are engineering. Furthermore, we highlight the need for understanding the baseline cell genotype and phenotype to appropriately understand the starting cell material and interpret and attribute the impact of engineering on cells. We emphasize that heterogeneity within a cell pool and the inherent variability in the cellular materials used for genome engineering are complex, but of high value to characterize and account for where possible, to move toward the potential of generating desired and predictable engineered products. Provided is a framework cause-and-effect diagram for CRISPR/Cas9 genome editing toward identifying and mitigating potential sources of variability. We encourage researchers to consider the variability of source materials and undertake strategies, which may include those described here, for detecting, attributing and minimizing additional sources of variability where possible toward the aim of fostering greater reliability, confidence and reproducibility in genome-engineering studies. Graphical Abstract.

作为基因组工程的源材料,细胞中可变性的存在和影响对于基因组工程过程的设计、执行和结果解释是重要的考虑因素。变异可能存在于基因型和表型水平,然而这些变异来源对基因组工程实验的影响可能不会被研究人员定期考虑。从这个角度来看,我们使用聚类规律间隔短回文重复(CRISPR)/CRISPR相关蛋白(Cas)对哺乳动物细胞进行基因组编辑,以提供细胞样本内部或跨细胞样本的变异如何误导研究人员对他们正在改造的细胞的期望的例子。此外,我们强调需要了解基线细胞基因型和表型,以适当地理解起始细胞材料,并解释和归因于工程对细胞的影响。我们强调,用于基因组工程的细胞池内的异质性和细胞材料的内在变异性是复杂的,但在可能的情况下,对其进行表征和解释具有很高的价值,从而朝着产生所需和可预测的工程产品的潜力迈进。提供了CRISPR/Cas9基因组编辑的框架因果关系图,以识别和减轻潜在的变异性来源。我们鼓励研究人员考虑源材料的可变性,并采取策略,其中可能包括此处所述的策略,以便在可能的情况下检测、归因和最小化额外的可变性来源,从而在基因组工程研究中培养更大的可靠性、信心和可重复性。图形抽象。
{"title":"Variability in genome-engineering source materials: consider your starting point.","authors":"Simona Patange,&nbsp;Sierra D Miller,&nbsp;Samantha D Maragh","doi":"10.1093/synbio/ysad003","DOIUrl":"https://doi.org/10.1093/synbio/ysad003","url":null,"abstract":"<p><p>The presence and impact of variability in cells as the source material for genome engineering are important to consider for the design, execution and interpretation of outcomes of a genome-engineering process. Variability may be present at the genotype and phenotype level, yet the impact of these sources of variability on a genome-engineering experiment may not be regularly considered by researchers. In this perspective, we use clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated protein (Cas) genome editing of mammalian cells to provide examples of how variation within or across cell samples may mislead a researcher in their expectations about the cells they are engineering. Furthermore, we highlight the need for understanding the baseline cell genotype and phenotype to appropriately understand the starting cell material and interpret and attribute the impact of engineering on cells. We emphasize that heterogeneity within a cell pool and the inherent variability in the cellular materials used for genome engineering are complex, but of high value to characterize and account for where possible, to move toward the potential of generating desired and predictable engineered products. Provided is a framework cause-and-effect diagram for CRISPR/Cas9 genome editing toward identifying and mitigating potential sources of variability. We encourage researchers to consider the variability of source materials and undertake strategies, which may include those described here, for detecting, attributing and minimizing additional sources of variability where possible toward the aim of fostering greater reliability, confidence and reproducibility in genome-engineering studies. <b>Graphical Abstract</b>.</p>","PeriodicalId":74902,"journal":{"name":"Synthetic biology (Oxford, England)","volume":"8 1","pages":"ysad003"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029982/pdf/ysad003.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9172013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fighting fire with fire: engineering a microbe into a therapeutic defense against drug-resistant biofilms. 以其人之道还治其人之身:将微生物改造成对抗耐药生物膜的治疗性防御。
Q2 BIOCHEMICAL RESEARCH METHODS Pub Date : 2023-01-01 DOI: 10.1093/synbio/ysad008
Charlotte Ayn Cialek
{"title":"Fighting fire with fire: engineering a microbe into a therapeutic defense against drug-resistant biofilms.","authors":"Charlotte Ayn Cialek","doi":"10.1093/synbio/ysad008","DOIUrl":"https://doi.org/10.1093/synbio/ysad008","url":null,"abstract":"","PeriodicalId":74902,"journal":{"name":"Synthetic biology (Oxford, England)","volume":"8 1","pages":"ysad008"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9839062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An injectable CRISPR therapy instructs B cells to produce anti-HIV antibodies. 一种可注射的CRISPR疗法指导B细胞产生抗hiv抗体。
Q2 BIOCHEMICAL RESEARCH METHODS Pub Date : 2022-11-08 eCollection Date: 2022-01-01 DOI: 10.1093/synbio/ysac027
Logan Thrasher Collins
© The Author(s) 2022. Published by Oxford University Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Although the immune system is well known as the guardian of the human body, certain infections and cancers can overwhelm its protective barriers. Over the past decade, scientists have developed genetic engineering tools that can enhance our immune systems to the point where they overcome such difficult threats. One success story in this area is the use of chimeric antigen receptor T cell (CAR T) therapy for blood cancers (1, 2). CAR T cells are engineered immune cells programmed to detect and destroy the cancer. In order to reprogram T cells, CAR T therapies require taking a blood sample out of a patient, shipping the sample to a laboratory, genetically modifying T cells within the sample, purifying the modified T cells, shipping them to the hospital and injecting them back into the patient. The cost, slowness and complexity of engineering immune cells outside of the body have limited accessibility of CAR T therapies and have challenged the expansion of this technology to the engineering of other immune cells such as B cells (3–5). To help overcome these barriers, a recent study was performed in Adi Barzel’s laboratory at Tel Aviv University and published in Nature Biotechnology. Nahmad et al. developed an injectable Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based gene therapy to directly modify B cells inside of the body, giving them the ability to produce an antibody that fights acquired immune deficiency syndrome (AIDS) infections (6). In the future, such an injection might make immune cell therapies cheaper and thus more accessible to everyone and may pave the way for a vaccine against AIDS or a potent treatment for people who already suffer from the disease. CRISPR acts as a biomolecular cut-and-paste system that can insert genetic instructions at desired locations within the genome. It uses a protein–RNA complex consisting of a Cas9 protein and a guide RNA (gRNA) to cut a sequence within the genome that is recognized by the gRNA. After the cut has been made, one can provide a new piece of DNA instructions that the cell will stitch into the cut site during repair. CRISPR makes genetic alteration of cells much easier by precisely targeting where to put new DNA into the genome. Nahmad et al. injected mice with engineered adeno–associated viruses (AAVs) for delivery of (i) a gene encoding an anti–human immunodeficiency virus (HIV) antibody and (ii) genes encoding CRISPR Cas9 and gRNA machinery. AAVs act as a type of delivery system for transporting DNA into human cells and are commonly used in gene ther
{"title":"An injectable CRISPR therapy instructs B cells to produce anti-HIV antibodies.","authors":"Logan Thrasher Collins","doi":"10.1093/synbio/ysac027","DOIUrl":"https://doi.org/10.1093/synbio/ysac027","url":null,"abstract":"© The Author(s) 2022. Published by Oxford University Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Although the immune system is well known as the guardian of the human body, certain infections and cancers can overwhelm its protective barriers. Over the past decade, scientists have developed genetic engineering tools that can enhance our immune systems to the point where they overcome such difficult threats. One success story in this area is the use of chimeric antigen receptor T cell (CAR T) therapy for blood cancers (1, 2). CAR T cells are engineered immune cells programmed to detect and destroy the cancer. In order to reprogram T cells, CAR T therapies require taking a blood sample out of a patient, shipping the sample to a laboratory, genetically modifying T cells within the sample, purifying the modified T cells, shipping them to the hospital and injecting them back into the patient. The cost, slowness and complexity of engineering immune cells outside of the body have limited accessibility of CAR T therapies and have challenged the expansion of this technology to the engineering of other immune cells such as B cells (3–5). To help overcome these barriers, a recent study was performed in Adi Barzel’s laboratory at Tel Aviv University and published in Nature Biotechnology. Nahmad et al. developed an injectable Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based gene therapy to directly modify B cells inside of the body, giving them the ability to produce an antibody that fights acquired immune deficiency syndrome (AIDS) infections (6). In the future, such an injection might make immune cell therapies cheaper and thus more accessible to everyone and may pave the way for a vaccine against AIDS or a potent treatment for people who already suffer from the disease. CRISPR acts as a biomolecular cut-and-paste system that can insert genetic instructions at desired locations within the genome. It uses a protein–RNA complex consisting of a Cas9 protein and a guide RNA (gRNA) to cut a sequence within the genome that is recognized by the gRNA. After the cut has been made, one can provide a new piece of DNA instructions that the cell will stitch into the cut site during repair. CRISPR makes genetic alteration of cells much easier by precisely targeting where to put new DNA into the genome. Nahmad et al. injected mice with engineered adeno–associated viruses (AAVs) for delivery of (i) a gene encoding an anti–human immunodeficiency virus (HIV) antibody and (ii) genes encoding CRISPR Cas9 and gRNA machinery. AAVs act as a type of delivery system for transporting DNA into human cells and are commonly used in gene ther","PeriodicalId":74902,"journal":{"name":"Synthetic biology (Oxford, England)","volume":" ","pages":"ysac027"},"PeriodicalIF":0.0,"publicationDate":"2022-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692189/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40711918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Piece by piece: making plant natural products accessible via heterologous biosynthesis. 一点一点:通过异源生物合成使植物天然产物可获得。
Q2 BIOCHEMICAL RESEARCH METHODS Pub Date : 2022-11-08 eCollection Date: 2022-01-01 DOI: 10.1093/synbio/ysac028
Kira J Tiedge
© The Author(s) 2022. Published by Oxford University Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Numerous of the products we use in our daily lives originally come from plants. These plant-derived natural products include flavors, fragrances and medicines, such as the fragrance limonene from citrus fruits or the antimalarial drug artemisinin. As we cannot grow enough plants to satisfy our demand for these compounds, researchers are trying to manufacture these natural products in their laboratories via expression in easy-to-culture plants, bacteria or yeast—so-called heterologous hosts. Like this, researchers can create cell factories that can make more than what is made by the natural host. For smaller molecules like limonene, this is a fairly streamlined process as only one enzyme needs to be added to a host to create such a cell factory (1). However, for making chemically more complex bioactive molecules, adding 10 or more enzymatic reactions is required. Cloning these reactions being hard enough, the real bottleneck for making chemically complex natural products is the fact that the enzymes catalyzing the biosynthesis are often not known and need to be identified first. Recently, a group of researchers from the Max Planck Institute for Chemical Ecology in Jena, Germany, managed to decipher the multistep biosynthetic pathway of strychnine, a toxic alkaloid which is famously used as poison in crime stories and as a pesticide in real-world applications. Furthermore, they were able to transfer all required precursor enzymes as well as nine newly identified enzymes together into a heterologous host for transient expression (2), delivering a blueprint for creating cell factories able to perform complex plant chemistry. Hong et al.’s achievement is remarkable for several reasons: plants have very complex genomes, making it hard to identify which genes are encoding the biosynthesis of a desired product. For example, a plant genome can host many gene candidates that could act as the code for a specific enzymatic reaction. Finding out which is the right one involves a laborious screening process: the selected genes need to be cloned into an expression vector and then transformed into an expression system, such as tobacco plants (Nicotiana benthamiana), where their catalytic activity can be confirmed. Although advances in deoxyribonucleic acid (DNA) synthesis have helped in overcoming bottlenecks in cloning plant DNA (3), many challenges of identifying all the puzzle pieces that allow a plant to make a desired product and putting them together in the right order remain. The complex biosynthetic pathway of strychnine had puzzled the
{"title":"Piece by piece: making plant natural products accessible via heterologous biosynthesis.","authors":"Kira J Tiedge","doi":"10.1093/synbio/ysac028","DOIUrl":"https://doi.org/10.1093/synbio/ysac028","url":null,"abstract":"© The Author(s) 2022. Published by Oxford University Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Numerous of the products we use in our daily lives originally come from plants. These plant-derived natural products include flavors, fragrances and medicines, such as the fragrance limonene from citrus fruits or the antimalarial drug artemisinin. As we cannot grow enough plants to satisfy our demand for these compounds, researchers are trying to manufacture these natural products in their laboratories via expression in easy-to-culture plants, bacteria or yeast—so-called heterologous hosts. Like this, researchers can create cell factories that can make more than what is made by the natural host. For smaller molecules like limonene, this is a fairly streamlined process as only one enzyme needs to be added to a host to create such a cell factory (1). However, for making chemically more complex bioactive molecules, adding 10 or more enzymatic reactions is required. Cloning these reactions being hard enough, the real bottleneck for making chemically complex natural products is the fact that the enzymes catalyzing the biosynthesis are often not known and need to be identified first. Recently, a group of researchers from the Max Planck Institute for Chemical Ecology in Jena, Germany, managed to decipher the multistep biosynthetic pathway of strychnine, a toxic alkaloid which is famously used as poison in crime stories and as a pesticide in real-world applications. Furthermore, they were able to transfer all required precursor enzymes as well as nine newly identified enzymes together into a heterologous host for transient expression (2), delivering a blueprint for creating cell factories able to perform complex plant chemistry. Hong et al.’s achievement is remarkable for several reasons: plants have very complex genomes, making it hard to identify which genes are encoding the biosynthesis of a desired product. For example, a plant genome can host many gene candidates that could act as the code for a specific enzymatic reaction. Finding out which is the right one involves a laborious screening process: the selected genes need to be cloned into an expression vector and then transformed into an expression system, such as tobacco plants (Nicotiana benthamiana), where their catalytic activity can be confirmed. Although advances in deoxyribonucleic acid (DNA) synthesis have helped in overcoming bottlenecks in cloning plant DNA (3), many challenges of identifying all the puzzle pieces that allow a plant to make a desired product and putting them together in the right order remain. The complex biosynthetic pathway of strychnine had puzzled the ","PeriodicalId":74902,"journal":{"name":"Synthetic biology (Oxford, England)","volume":" ","pages":"ysac028"},"PeriodicalIF":0.0,"publicationDate":"2022-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700380/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40504937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An arrayed CRISPR screen reveals Myc depletion to increase productivity of difficult-to-express complex antibodies in CHO cells. 排列的CRISPR筛选显示Myc耗尽增加CHO细胞中难以表达的复杂抗体的生产力。
Q2 BIOCHEMICAL RESEARCH METHODS Pub Date : 2022-11-03 eCollection Date: 2022-01-01 DOI: 10.1093/synbio/ysac026
Niels Bauer, Benedikt Oswald, Maximilian Eiche, Lisa Schiller, Emma Langguth, Christian Schantz, Andrea Osterlehner, Amy Shen, Shahram Misaghi, Julian Stingele, Simon Ausländer

Complex therapeutic antibody formats, such as bispecifics (bsAbs) or cytokine fusions, may provide new treatment options in diverse disease areas. However, the manufacturing yield of these complex antibody formats in Chinese Hamster Ovary (CHO) cells is lower than monoclonal antibodies due to challenges in expression levels and potential formation of side products. To overcome these limitations, we performed a clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9)-based knockout (KO) arrayed screening of 187 target genes in two CHO clones expressing two different complex antibody formats in a production-mimicking set-up. Our findings revealed that Myc depletion drastically increased product expression (>40%) by enhancing cell-specific productivity. The Myc-depleted cells displayed decreased cell densities together with substantially higher product titers in industrially-relevant bioprocesses using ambr15 and ambr250 bioreactors. Similar effects were observed across multiple different clones, each expressing a distinct complex antibody format. Our findings reinforce the mutually exclusive relationship between growth and production phenotypes and provide a targeted cell engineering approach to impact productivity without impairing product quality. We anticipate that CRISPR/Cas9-based CHO host cell engineering will transform our ability to increase manufacturing yield of high-value complex biotherapeutics.

复杂的治疗性抗体形式,如双特异性抗体(bsAbs)或细胞因子融合抗体,可能为不同疾病领域提供新的治疗选择。然而,在中国仓鼠卵巢(CHO)细胞中,由于表达水平的挑战和潜在的副产物的形成,这些复合抗体格式的制造产量低于单克隆抗体。为了克服这些限制,我们在模拟生产的环境中,对两个CHO克隆中表达两种不同的复合抗体格式的187个靶基因进行了集群规则间隔短重复序列(CRISPR)/CRISPR相关蛋白9 (Cas9)敲除(KO)阵列筛选。我们的研究结果表明,Myc缺失通过提高细胞特异性生产力显著增加了产物表达(>40%)。在使用ambr15和ambr250生物反应器的工业相关生物过程中,myc耗尽的细胞显示出细胞密度降低,同时产品滴度显著提高。在多个不同的克隆中观察到类似的效果,每个克隆表达一种不同的复杂抗体格式。我们的研究结果加强了生长和生产表型之间的互斥关系,并提供了一种有针对性的细胞工程方法来影响生产力而不损害产品质量。我们预计基于CRISPR/ cas9的CHO宿主细胞工程将改变我们提高高价值复杂生物治疗药物生产产量的能力。
{"title":"An arrayed CRISPR screen reveals Myc depletion to increase productivity of difficult-to-express complex antibodies in CHO cells.","authors":"Niels Bauer,&nbsp;Benedikt Oswald,&nbsp;Maximilian Eiche,&nbsp;Lisa Schiller,&nbsp;Emma Langguth,&nbsp;Christian Schantz,&nbsp;Andrea Osterlehner,&nbsp;Amy Shen,&nbsp;Shahram Misaghi,&nbsp;Julian Stingele,&nbsp;Simon Ausländer","doi":"10.1093/synbio/ysac026","DOIUrl":"https://doi.org/10.1093/synbio/ysac026","url":null,"abstract":"<p><p>Complex therapeutic antibody formats, such as bispecifics (bsAbs) or cytokine fusions, may provide new treatment options in diverse disease areas. However, the manufacturing yield of these complex antibody formats in Chinese Hamster Ovary (CHO) cells is lower than monoclonal antibodies due to challenges in expression levels and potential formation of side products. To overcome these limitations, we performed a clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9)-based knockout (KO) arrayed screening of 187 target genes in two CHO clones expressing two different complex antibody formats in a production-mimicking set-up. Our findings revealed that Myc depletion drastically increased product expression (>40%) by enhancing cell-specific productivity. The Myc-depleted cells displayed decreased cell densities together with substantially higher product titers in industrially-relevant bioprocesses using ambr15 and ambr250 bioreactors. Similar effects were observed across multiple different clones, each expressing a distinct complex antibody format. Our findings reinforce the mutually exclusive relationship between growth and production phenotypes and provide a targeted cell engineering approach to impact productivity without impairing product quality. We anticipate that CRISPR/Cas9-based CHO host cell engineering will transform our ability to increase manufacturing yield of high-value complex biotherapeutics.</p>","PeriodicalId":74902,"journal":{"name":"Synthetic biology (Oxford, England)","volume":" ","pages":"ysac026"},"PeriodicalIF":0.0,"publicationDate":"2022-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/02/0d/ysac026.PMC9700384.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40504936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
High-efficiency retron-mediated single-stranded DNA production in plants. 植物中逆转录酶介导的高效单链DNA生产。
Q2 BIOCHEMICAL RESEARCH METHODS Pub Date : 2022-11-01 eCollection Date: 2022-01-01 DOI: 10.1093/synbio/ysac025
Wenjun Jiang, Gundra Sivakrishna Rao, Rashid Aman, Haroon Butt, Radwa Kamel, Khalid Sedeek, Magdy M Mahfouz

Retrons are a class of retroelements that produce multicopy single-stranded DNA (ssDNA) and participate in anti-phage defenses in bacteria. Retrons have been harnessed for the overproduction of ssDNA, genome engineering and directed evolution in bacteria, yeast and mammalian cells. Retron-mediated ssDNA production in plants could unlock their potential applications in plant biotechnology. For example, ssDNA can be used as a template for homology-directed repair (HDR) in several organisms. However, current gene editing technologies rely on the physical delivery of synthetic ssDNA, which limits their applications. Here, we demonstrated retron-mediated overproduction of ssDNA in Nicotiana benthamiana. Additionally, we tested different retron architectures for improved ssDNA production and identified a new retron architecture that resulted in greater ssDNA abundance. Furthermore, co-expression of the gene encoding the ssDNA-protecting protein VirE2 from Agrobacterium tumefaciens with the retron systems resulted in a 10.7-fold increase in ssDNA production in vivo. We also demonstrated clustered regularly interspaced short palindromic repeats-retron-coupled ssDNA overproduction and targeted HDR in N. benthamiana. Overall, we present an efficient approach for in vivo ssDNA production in plants, which can be harnessed for biotechnological applications. Graphical Abstract.

逆转录因子是一类产生多拷贝单链DNA (ssDNA)并参与细菌抗噬菌体防御的逆转录因子。逆转录酶已被用于细菌、酵母和哺乳动物细胞中ssDNA的过量生产、基因组工程和定向进化。逆转录酶介导的ssDNA在植物生物技术中的应用前景广阔。例如,ssDNA可以在一些生物体中用作同源定向修复(HDR)的模板。然而,目前的基因编辑技术依赖于合成ssDNA的物理传递,这限制了它们的应用。在这里,我们证明了逆转录介导的ssDNA在烟叶中过量产生。此外,我们测试了不同的逆转录体系结构,以改善ssDNA的产生,并确定了一种新的逆转录体系结构,可以提高ssDNA的丰度。此外,肿瘤农杆菌中编码ssDNA保护蛋白VirE2的基因与逆转录系统共表达,导致体内ssDNA产量增加10.7倍。我们还证明了benthamiana中聚集的规则间隔短回文重复-反转录偶联的ssDNA过剩和靶向HDR。总之,我们提出了一种在植物体内生产ssDNA的有效方法,可以用于生物技术应用。图形抽象。
{"title":"High-efficiency retron-mediated single-stranded DNA production in plants.","authors":"Wenjun Jiang,&nbsp;Gundra Sivakrishna Rao,&nbsp;Rashid Aman,&nbsp;Haroon Butt,&nbsp;Radwa Kamel,&nbsp;Khalid Sedeek,&nbsp;Magdy M Mahfouz","doi":"10.1093/synbio/ysac025","DOIUrl":"https://doi.org/10.1093/synbio/ysac025","url":null,"abstract":"<p><p>Retrons are a class of retroelements that produce multicopy single-stranded DNA (ssDNA) and participate in anti-phage defenses in bacteria. Retrons have been harnessed for the overproduction of ssDNA, genome engineering and directed evolution in bacteria, yeast and mammalian cells. Retron-mediated ssDNA production in plants could unlock their potential applications in plant biotechnology. For example, ssDNA can be used as a template for homology-directed repair (HDR) in several organisms. However, current gene editing technologies rely on the physical delivery of synthetic ssDNA, which limits their applications. Here, we demonstrated retron-mediated overproduction of ssDNA in <i>Nicotiana benthamiana</i>. Additionally, we tested different retron architectures for improved ssDNA production and identified a new retron architecture that resulted in greater ssDNA abundance. Furthermore, co-expression of the gene encoding the ssDNA-protecting protein VirE2 from <i>Agrobacterium tumefaciens</i> with the retron systems resulted in a 10.7-fold increase in ssDNA production <i>in vivo</i>. We also demonstrated clustered regularly interspaced short palindromic repeats-retron-coupled ssDNA overproduction and targeted HDR in <i>N. benthamiana</i>. Overall, we present an efficient approach for <i>in vivo</i> ssDNA production in plants, which can be harnessed for biotechnological applications. <b>Graphical Abstract</b>.</p>","PeriodicalId":74902,"journal":{"name":"Synthetic biology (Oxford, England)","volume":" ","pages":"ysac025"},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ab/6f/ysac025.PMC9700382.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40504938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Mouse chromosomes get supersized but find their limits. 老鼠的染色体会变大,但也会有极限。
Q2 BIOCHEMICAL RESEARCH METHODS Pub Date : 2022-10-25 eCollection Date: 2022-01-01 DOI: 10.1093/synbio/ysac024
David M Truong
© The Author(s) 2022. Published by Oxford University Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Humans diverged from primates when an ancestral chromosomal fusion—the event when two chromosomes join together to form one—gave us 23 instead of 24 sets of chromosomes. In muntjac deer, small deer native to South and Southeast Asia, chromosome fusions occurred so often that Indian muntjacs have only 3 chromosomes, whereas Chinese muntjacs have 23 (1). Fusions matter not only during the evolution of species but can also cause diseases such as cancer or Down’s syndrome. While fusions occur often in nature, engineering events like these on purpose have been difficult to do. The field of synthetic genomics attempts feats like this, along with building new designer chromosomes for applications in medicine, agriculture and industrial processing. Completely synthetic genomes have been built for bacteria (2), as well as for yeast (2). Additionally, it was shown that all 16 yeast chromosomes can be fused into one single chromosome 12 megabases long (3). Besides these achievements, it remained an open question what the actual size limit of a single chromosome would be, for example, whether the 100–200 megabase mammalian chromosomes could be fused and whether changes like these would persist through multiple generations. Answers could be used to model speciation and human diseases, as well as biologically ‘contain’ engineered organisms from natural populations. In a groundbreaking new study (4), researchers from the Chinese Academy of Sciences have generated the largest designed fusion chromosomes so far reported in mice as their research model. To technically achieve this, they used Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) to make targeted DNA breaks. These breaks would induce recombination—a natural repair process of the cell—thereby fusing the two largest mouse chromosomes 1 and 2 into a single one, in two different orientations, followed by fusing medium size chromosomes 4 and 5. The longest of these chromosomes was 377 megabases long and functional. In addition, they accomplished all this engineering in haploid mouse embryonic stem cells (i.e. cells with only one set of chromosomes), showing the potential to make mice easier to engineer using haploid cells in a Petri dish. Although the authors could generate heterozygous embryos with the largest fused chromosomes, one fused orientation was lethal to the developing embryo, while embryos of the other orientation grew to adulthood. Yet, the resultant mice could not breed homozygous offspring. Surprisingly, the 308 megabase medium-sized fused chromosome mice coul
{"title":"Mouse chromosomes get supersized but find their limits.","authors":"David M Truong","doi":"10.1093/synbio/ysac024","DOIUrl":"https://doi.org/10.1093/synbio/ysac024","url":null,"abstract":"© The Author(s) 2022. Published by Oxford University Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Humans diverged from primates when an ancestral chromosomal fusion—the event when two chromosomes join together to form one—gave us 23 instead of 24 sets of chromosomes. In muntjac deer, small deer native to South and Southeast Asia, chromosome fusions occurred so often that Indian muntjacs have only 3 chromosomes, whereas Chinese muntjacs have 23 (1). Fusions matter not only during the evolution of species but can also cause diseases such as cancer or Down’s syndrome. While fusions occur often in nature, engineering events like these on purpose have been difficult to do. The field of synthetic genomics attempts feats like this, along with building new designer chromosomes for applications in medicine, agriculture and industrial processing. Completely synthetic genomes have been built for bacteria (2), as well as for yeast (2). Additionally, it was shown that all 16 yeast chromosomes can be fused into one single chromosome 12 megabases long (3). Besides these achievements, it remained an open question what the actual size limit of a single chromosome would be, for example, whether the 100–200 megabase mammalian chromosomes could be fused and whether changes like these would persist through multiple generations. Answers could be used to model speciation and human diseases, as well as biologically ‘contain’ engineered organisms from natural populations. In a groundbreaking new study (4), researchers from the Chinese Academy of Sciences have generated the largest designed fusion chromosomes so far reported in mice as their research model. To technically achieve this, they used Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) to make targeted DNA breaks. These breaks would induce recombination—a natural repair process of the cell—thereby fusing the two largest mouse chromosomes 1 and 2 into a single one, in two different orientations, followed by fusing medium size chromosomes 4 and 5. The longest of these chromosomes was 377 megabases long and functional. In addition, they accomplished all this engineering in haploid mouse embryonic stem cells (i.e. cells with only one set of chromosomes), showing the potential to make mice easier to engineer using haploid cells in a Petri dish. Although the authors could generate heterozygous embryos with the largest fused chromosomes, one fused orientation was lethal to the developing embryo, while embryos of the other orientation grew to adulthood. Yet, the resultant mice could not breed homozygous offspring. Surprisingly, the 308 megabase medium-sized fused chromosome mice coul","PeriodicalId":74902,"journal":{"name":"Synthetic biology (Oxford, England)","volume":" ","pages":"ysac024"},"PeriodicalIF":0.0,"publicationDate":"2022-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/19/9b/ysac024.PMC9659764.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40687767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
basicsynbio and the BASIC SEVA collection: software and vectors for an established DNA assembly method. basicsynbio和BASIC SEVA集合:用于建立DNA组装方法的软件和载体。
Q2 BIOCHEMICAL RESEARCH METHODS Pub Date : 2022-10-11 eCollection Date: 2022-01-01 DOI: 10.1093/synbio/ysac023
Matthew C Haines, Benedict Carling, James Marshall, Vasily A Shenshin, Geoff S Baldwin, Paul Freemont, Marko Storch

Standardized deoxyribonucleic acid (DNA) assembly methods utilizing modular components provide a powerful framework to explore designs and iterate through Design-Build-Test-Learn cycles. Biopart Assembly Standard for Idempotent Cloning (BASIC) DNA assembly uses modular parts and linkers, is highly accurate, easy to automate, free for academic and commercial use and enables hierarchical assemblies through an idempotent format. These features enable applications including pathway engineering, ribosome binding site (RBS) tuning, fusion protein engineering and multiplexed guide ribonucleic acid (RNA) expression. In this work, we present basicsynbio, open-source software encompassing a Web App (https://basicsynbio.web.app/) and Python Package (https://github.com/LondonBiofoundry/basicsynbio), enabling BASIC construct design via simple drag-and-drop operations or programmatically. With basicsynbio, users can access commonly used BASIC parts and linkers while designing new parts and assemblies with exception handling for common errors. Users can export sequence data and create instructions for manual or acoustic liquid-handling platforms. Instruction generation relies on the BasicBuild Open Standard, which is parsed for bespoke workflows and is serializable in JavaScript Object Notation for transfer and storage. We demonstrate basicsynbio, assembling 30 vectors using sequences including modules from the Standard European Vector Architecture (SEVA). The BASIC SEVA vector collection is compatible with BASIC and Golden Gate using BsaI. Vectors contain one of six antibiotic resistance markers and five origins of replication from different compatibility groups. The collection is available via Addgene under an OpenMTA agreement. Furthermore, vector sequences are available from within the basicsynbio application programming interface with other collections of parts and linkers, providing a powerful environment for designing assemblies for bioengineering applications. Graphical Abstract.

利用模块化组件的标准化脱氧核糖核酸(DNA)组装方法为探索设计和通过设计-构建-测试-学习循环迭代提供了强大的框架。DNA组装使用模块化部件和连接器,高度准确,易于自动化,免费用于学术和商业用途,并通过幂等格式实现分层组装。这些特性使得包括途径工程、核糖体结合位点(RBS)调整、融合蛋白工程和多路引导核糖核酸(RNA)表达在内的应用成为可能。在这项工作中,我们介绍了基本的合成,开源软件,包括Web应用程序(https://basicsynbio.web.app/)和Python包(https://github.com/LondonBiofoundry/basicsynbio),通过简单的拖放操作或编程实现BASIC构造设计。使用basicsynbio,用户可以在设计新部件和组件时访问常用的BASIC部件和连接器,并对常见错误进行异常处理。用户可以导出序列数据并创建手动或声学液体处理平台的说明。指令生成依赖于BasicBuild开放标准,该标准针对定制工作流进行解析,并可在JavaScript对象符号中序列化,以便传输和存储。我们演示了基本的合成,使用包括来自标准欧洲载体架构(SEVA)的模块在内的序列组装30个载体。BASIC SEVA矢量集合与BASIC和使用BsaI的Golden Gate兼容。载体包含六种抗生素耐药性标记之一和来自不同相容性群体的五种复制起源。根据OpenMTA协议,该集合可通过Addgene获得。此外,载体序列可从基本合成生物应用程序编程接口中与其他部件和连接器集合使用,为生物工程应用程序设计组件提供了强大的环境。图形抽象。
{"title":"basicsynbio and the BASIC SEVA collection: software and vectors for an established DNA assembly method.","authors":"Matthew C Haines,&nbsp;Benedict Carling,&nbsp;James Marshall,&nbsp;Vasily A Shenshin,&nbsp;Geoff S Baldwin,&nbsp;Paul Freemont,&nbsp;Marko Storch","doi":"10.1093/synbio/ysac023","DOIUrl":"https://doi.org/10.1093/synbio/ysac023","url":null,"abstract":"<p><p>Standardized deoxyribonucleic acid (DNA) assembly methods utilizing modular components provide a powerful framework to explore designs and iterate through Design-Build-Test-Learn cycles. Biopart Assembly Standard for Idempotent Cloning (BASIC) DNA assembly uses modular parts and linkers, is highly accurate, easy to automate, free for academic and commercial use and enables hierarchical assemblies through an idempotent format. These features enable applications including pathway engineering, ribosome binding site (RBS) tuning, fusion protein engineering and multiplexed guide ribonucleic acid (RNA) expression. In this work, we present basicsynbio, open-source software encompassing a Web App (https://basicsynbio.web.app/) and Python Package (https://github.com/LondonBiofoundry/basicsynbio), enabling BASIC construct design via simple drag-and-drop operations or programmatically. With basicsynbio, users can access commonly used BASIC parts and linkers while designing new parts and assemblies with exception handling for common errors. Users can export sequence data and create instructions for manual or acoustic liquid-handling platforms. Instruction generation relies on the BasicBuild Open Standard, which is parsed for bespoke workflows and is serializable in JavaScript Object Notation for transfer and storage. We demonstrate basicsynbio, assembling 30 vectors using sequences including modules from the Standard European Vector Architecture (SEVA). The BASIC SEVA vector collection is compatible with BASIC and Golden Gate using BsaI. Vectors contain one of six antibiotic resistance markers and five origins of replication from different compatibility groups. The collection is available via Addgene under an OpenMTA agreement. Furthermore, vector sequences are available from within the basicsynbio application programming interface with other collections of parts and linkers, providing a powerful environment for designing assemblies for bioengineering applications. <b>Graphical Abstract</b>.</p>","PeriodicalId":74902,"journal":{"name":"Synthetic biology (Oxford, England)","volume":" ","pages":"ysac023"},"PeriodicalIF":0.0,"publicationDate":"2022-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664905/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40687691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Could a simple model of COVID-19 infections be the key to designing better virus-based therapies? 一个简单的COVID-19感染模型能否成为设计更好的基于病毒的治疗方法的关键?
Q2 BIOCHEMICAL RESEARCH METHODS Pub Date : 2022-09-10 eCollection Date: 2022-01-01 DOI: 10.1093/synbio/ysac019
Connor R King
© The Author(s) 2022. Published by Oxford University Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Since the emergence of COVID-19, the spotlight on viruses has become negative. However, viruses are not only our enemies, due to their ability to deliver DNA and RNA into cells, viruses can also be repurposed as therapeutics. This ability is already used to treat genetic diseases and cancer (2, 4). However, an important factor that is often overlooked when developing virus-based therapies is the fact that each patient’s immune system might respond differently to the treatment which can determine its effectiveness (3). Recently, the Ke Lab at Los Alamos National Laboratory developed a simplistic model of the immune response to SARS-CoV-2 infection that can explain why some individuals have severe symptoms while others quickly resolve the infection (1). The simplicity of this model suggests that one day it could not only help understand viral infections but help improve virus-based therapies. Current designs for virus-based therapeutics mainly focused on the delivery system itself. Much like if you were designing a system to deliver medicine to houses, you might first want to optimize the delivery vehicle to be used for delivering the medicine and identify routes for the delivery. Now imagine that this system was developed just around the delivery of the medication itself without consideration of what might happen when the medicine is delivered. If you deliver this medicine to a house that is, much like a cell, unaware of why the medicine is coming, the recipient may dispose of the said medication. Since the injection of DNA or RNA from a virus into a cell is typically associated with a disease, it is reasonable to assume that the cell has processes at hand that interfere with virus-based treatments. The model from the Ke lab might help therapy-designers to predict and mitigate these processes just as the model is able to explain why some people get severe COVID-19 and others do not. The focus of the model is the immune response generated by the molecular footprint left by the viral disease. This footprint results from the viral infection itself but is also generated by cells being damaged by the immune system. Both contribute to sustaining an active immune response in patients. The model simplifies many of the processes that generate and remove this footprint in order to reduce complexity. Their approach to making the model simple can be compared to trying to plan out how long it takes to drive from San Francisco to Los Angeles. There are many factors that contribute to how quickly one can drive—traffic and headwind—but one could p
{"title":"Could a simple model of COVID-19 infections be the key to designing better virus-based therapies?","authors":"Connor R King","doi":"10.1093/synbio/ysac019","DOIUrl":"https://doi.org/10.1093/synbio/ysac019","url":null,"abstract":"© The Author(s) 2022. Published by Oxford University Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Since the emergence of COVID-19, the spotlight on viruses has become negative. However, viruses are not only our enemies, due to their ability to deliver DNA and RNA into cells, viruses can also be repurposed as therapeutics. This ability is already used to treat genetic diseases and cancer (2, 4). However, an important factor that is often overlooked when developing virus-based therapies is the fact that each patient’s immune system might respond differently to the treatment which can determine its effectiveness (3). Recently, the Ke Lab at Los Alamos National Laboratory developed a simplistic model of the immune response to SARS-CoV-2 infection that can explain why some individuals have severe symptoms while others quickly resolve the infection (1). The simplicity of this model suggests that one day it could not only help understand viral infections but help improve virus-based therapies. Current designs for virus-based therapeutics mainly focused on the delivery system itself. Much like if you were designing a system to deliver medicine to houses, you might first want to optimize the delivery vehicle to be used for delivering the medicine and identify routes for the delivery. Now imagine that this system was developed just around the delivery of the medication itself without consideration of what might happen when the medicine is delivered. If you deliver this medicine to a house that is, much like a cell, unaware of why the medicine is coming, the recipient may dispose of the said medication. Since the injection of DNA or RNA from a virus into a cell is typically associated with a disease, it is reasonable to assume that the cell has processes at hand that interfere with virus-based treatments. The model from the Ke lab might help therapy-designers to predict and mitigate these processes just as the model is able to explain why some people get severe COVID-19 and others do not. The focus of the model is the immune response generated by the molecular footprint left by the viral disease. This footprint results from the viral infection itself but is also generated by cells being damaged by the immune system. Both contribute to sustaining an active immune response in patients. The model simplifies many of the processes that generate and remove this footprint in order to reduce complexity. Their approach to making the model simple can be compared to trying to plan out how long it takes to drive from San Francisco to Los Angeles. There are many factors that contribute to how quickly one can drive—traffic and headwind—but one could p","PeriodicalId":74902,"journal":{"name":"Synthetic biology (Oxford, England)","volume":" ","pages":"ysac019"},"PeriodicalIF":0.0,"publicationDate":"2022-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/07/5c/ysac019.PMC9518665.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40390049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A toolkit for enhanced reproducibility of RNASeq analysis for synthetic biologists. 为合成生物学家提高RNASeq分析可重复性的工具包。
Q2 BIOCHEMICAL RESEARCH METHODS Pub Date : 2022-08-23 eCollection Date: 2022-01-01 DOI: 10.1093/synbio/ysac012
Benjamin J Garcia, Joshua Urrutia, George Zheng, Diveena Becker, Carolyn Corbet, Paul Maschhoff, Alexander Cristofaro, Niall Gaffney, Matthew Vaughn, Uma Saxena, Yi-Pei Chen, D Benjamin Gordon, Mohammed Eslami

Sequencing technologies, in particular RNASeq, have become critical tools in the design, build, test and learn cycle of synthetic biology. They provide a better understanding of synthetic designs, and they help identify ways to improve and select designs. While these data are beneficial to design, their collection and analysis is a complex, multistep process that has implications on both discovery and reproducibility of experiments. Additionally, tool parameters, experimental metadata, normalization of data and standardization of file formats present challenges that are computationally intensive. This calls for high-throughput pipelines expressly designed to handle the combinatorial and longitudinal nature of synthetic biology. In this paper, we present a pipeline to maximize the analytical reproducibility of RNASeq for synthetic biologists. We also explore the impact of reproducibility on the validation of machine learning models. We present the design of a pipeline that combines traditional RNASeq data processing tools with structured metadata tracking to allow for the exploration of the combinatorial design in a high-throughput and reproducible manner. We then demonstrate utility via two different experiments: a control comparison experiment and a machine learning model experiment. The first experiment compares datasets collected from identical biological controls across multiple days for two different organisms. It shows that a reproducible experimental protocol for one organism does not guarantee reproducibility in another. The second experiment quantifies the differences in experimental runs from multiple perspectives. It shows that the lack of reproducibility from these different perspectives can place an upper bound on the validation of machine learning models trained on RNASeq data. Graphical Abstract.

测序技术,特别是RNASeq,已经成为合成生物学设计、构建、测试和学习周期的关键工具。它们提供了对合成设计的更好理解,并帮助确定改进和选择设计的方法。虽然这些数据有利于设计,但它们的收集和分析是一个复杂的、多步骤的过程,对实验的发现和可重复性都有影响。此外,工具参数、实验元数据、数据规范化和文件格式标准化都是计算密集型的挑战。这需要高通量的管道,专门设计来处理合成生物学的组合和纵向性质。在本文中,我们提出了一个管道,以最大限度地提高RNASeq的分析可重复性合成生物学家。我们还探讨了可重复性对机器学习模型验证的影响。我们提出了一种管道的设计,该管道将传统的RNASeq数据处理工具与结构化元数据跟踪相结合,以允许以高通量和可重复的方式探索组合设计。然后,我们通过两个不同的实验来证明实用性:一个控制比较实验和一个机器学习模型实验。第一个实验比较了从两种不同生物的相同生物对照中收集的数据集。这表明一种生物的可重复性实验方案并不保证在另一种生物中的可重复性。第二个实验从多个角度量化了实验运行的差异。这表明,从这些不同的角度来看,缺乏可重复性可以为在RNASeq数据上训练的机器学习模型的验证设置上限。图形抽象。
{"title":"A toolkit for enhanced reproducibility of RNASeq analysis for synthetic biologists.","authors":"Benjamin J Garcia,&nbsp;Joshua Urrutia,&nbsp;George Zheng,&nbsp;Diveena Becker,&nbsp;Carolyn Corbet,&nbsp;Paul Maschhoff,&nbsp;Alexander Cristofaro,&nbsp;Niall Gaffney,&nbsp;Matthew Vaughn,&nbsp;Uma Saxena,&nbsp;Yi-Pei Chen,&nbsp;D Benjamin Gordon,&nbsp;Mohammed Eslami","doi":"10.1093/synbio/ysac012","DOIUrl":"https://doi.org/10.1093/synbio/ysac012","url":null,"abstract":"<p><p>Sequencing technologies, in particular RNASeq, have become critical tools in the design, build, test and learn cycle of synthetic biology. They provide a better understanding of synthetic designs, and they help identify ways to improve and select designs. While these data are beneficial to design, their collection and analysis is a complex, multistep process that has implications on both discovery and reproducibility of experiments. Additionally, tool parameters, experimental metadata, normalization of data and standardization of file formats present challenges that are computationally intensive. This calls for high-throughput pipelines expressly designed to handle the combinatorial and longitudinal nature of synthetic biology. In this paper, we present a pipeline to maximize the analytical reproducibility of RNASeq for synthetic biologists. We also explore the impact of reproducibility on the validation of machine learning models. We present the design of a pipeline that combines traditional RNASeq data processing tools with structured metadata tracking to allow for the exploration of the combinatorial design in a high-throughput and reproducible manner. We then demonstrate utility via two different experiments: a control comparison experiment and a machine learning model experiment. The first experiment compares datasets collected from identical biological controls across multiple days for two different organisms. It shows that a reproducible experimental protocol for one organism does not guarantee reproducibility in another. The second experiment quantifies the differences in experimental runs from multiple perspectives. It shows that the lack of reproducibility from these different perspectives can place an upper bound on the validation of machine learning models trained on RNASeq data. Graphical Abstract.</p>","PeriodicalId":74902,"journal":{"name":"Synthetic biology (Oxford, England)","volume":" ","pages":"ysac012"},"PeriodicalIF":0.0,"publicationDate":"2022-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4f/a8/ysac012.PMC9408027.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33444691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Synthetic biology (Oxford, England)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1